← Markets

T. Rowe Price Health Sciences Fund

PRHSX · NASDAQ

Market closed$90.05$0.320000 (+0.36%)

Key statistics

Previous close$89.73
Open$90.05
Day high$90.05
Day low$90.05
52-week high$95.70
52-week low$74.50
Market cap11.95B
Volume—
Average volume—
P/E ratio32.21
Forward P/E—
EPS2.80
Dividend yield0.00%

Market context

Why it moved

PRHSX, a T. Rowe Price health sciences fund, edged higher likely driven by broad positive sentiment in the healthcare sector amid favorable market conditions and continued investor interest in health sciences equities.

Ulta

What is happening

Recent company-specific developments and publisher coverage.

July 14, 2026T. Rowe Price Health Sciences Fund held steady after hours as broader financial services stocks navigated a mixed session shaped by strong Wall Street bank earnings and a cooler-than-expected June CPI print. JPMorgan posted a record quarterly profit and Goldman Sachs beat estimates on a trading and dealmaking surge, lifting sentiment in financial services broadly, though Morningstar noted the sector remains the second-worst performer over the past year amid AI disruption concerns and private credit worries. Meanwhile, ongoing U.S.-Iran tensions and elevated market valuations kept investors cautious heading into a critical stretch of Q2 earnings.

-1.03356

June 30, 2026T. Rowe Price Health Sciences Fund closed the first half of 2026 on a constructive note, benefiting from a notable rotation into healthcare that gained momentum last week as tech stocks sold off sharply. The healthcare sector surged nearly 8% in June amid aggressive sector rotation out of large-cap technology names, with investors pivoting to 'old economy' plays including biotech and pharma amid AI spending uncertainty and geopolitical volatility tied to the U.S.-Iran conflict. The broader market closed Q2 strongly—the S&P 500's best quarterly performance in years—though financial sector headwinds emerged as Oppenheimer downgraded major banks including Goldman Sachs and Morgan Stanley.
June 25, 2026T. Rowe Price Health Sciences Fund closed essentially unchanged as the broader market found its footing following a sharp tech-led selloff earlier in the week. Micron Technology's blowout earnings reignited AI optimism and lifted semiconductor stocks sharply, while UBS noted healthcare's relative resilience as a standout amid ongoing volatility. The financials sector, which classifies asset managers like T. Rowe Price, faced modest headwinds, with XLF declining on the day even as after-hours trading showed a slight recovery.

1.58841

June 24, 2026T. Rowe Price Health Sciences Fund is trading flat amid a volatile broader market environment, as tech-driven turbulence and AI spending concerns ripple across equities. A sharp global chip sell-off on Tuesday—driven by stretched valuations in AI-related names and a Nasdaq decline of nearly 3%—has weighed on investor sentiment heading into Wednesday's session, though healthcare-focused funds like PRHSX offer some insulation from the tech volatility. Markets are also watching Federal Reserve rate expectations, with Bank of America forecasting three rate hikes this year, adding a cautious macro backdrop for growth-oriented health sciences holdings.
T. Rowe Price · February 5, 2026Health care’s next chapter: Opportunities in an era of transformationU.S. News - Money · January 6, 20256 Best Healthcare Funds and ETFs to Buy NowU.S. News - Money · August 28, 2024The Best T. Rowe Price Funds for RetirementKiplinger · October 7, 20205 Best Health Care Mutual Funds for the Long Run

Peers

S&P 500SPX · $7,457.69-1.01%T. Rowe Price International StockPRITX · $22.71-1.17%State Street Equity 500 Index FundSSSYX · $558.82-1.01%T. Rowe Price Mid-Cap Value FundTRMCX · $38.52-0.41%T. Rowe Price Retirement 2020 FundTRRBX · $20.86-0.38%USAA 500 Index FundUSPRX · $90.37-1.00%Vanguard Target Retirement 2065 FundVLXVX · $43.89-0.81%Allspring Special Mid Cap Value FundWFMDX · $50.68-0.65%Allspring Special Mid Cap Value R6WFPRX · $51.39-0.64%